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Abstract
Vaccines against pertussis have been available for more than 60 years. Nonetheless, this
highly contagious disease is reemerging even in countries with high vaccination coverage.
Genetic changes of Bordetella pertussis over time have been suggested to contribute to the
resurgence of pertussis, as these changes may favor escape from vaccine-induced immu-
nity. Nonetheless, studies on the effects of these bacterial changes on the immune response
are limited. Here, we characterize innate immune recognition and activation by a collection of
genetically diverse B. pertussis strains isolated from Dutch pertussis patients before and
after the introduction of the pertussis vaccines. For this purpose, we used HEK-Blue cells
transfected with human pattern recognition receptors TLR2, TLR4, NOD2 and NOD1 as a
high throughput system for screening innate immune recognition of more than 90 bacterial
strains. Physiologically relevant human monocyte derived dendritic cells (moDC), purified
from peripheral blood of healthy donors were also used. Findings indicate that, in addition to
inducing TLR2 and TLR4 signaling, all B. pertussis strains activate the NOD-like receptor
NOD2 but not NOD1. Furthermore, we observed a significant increase in TLR2 and NOD2,
but not TLR4, activation by strains circulating after the introduction of pertussis vaccines.
When using moDC, we observed that the recently circulating strains induced increased acti-
vation of these cells with a dominant IL-10 production. In addition, we observed an increased
expression of surface markers including the regulatory molecule PD-L1. Expression of PD-
L1 was decreased upon blocking TLR2. These in vitro findings suggest that emerging B. per-
tussis strains have evolved to dampen the vaccine-induced inflammatory response, which
would benefit survival and transmission of this pathogen. Understanding how this disease
has resurged in a highly vaccinated population is crucial for the design of improved vaccines
against pertussis.
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Introduction
Bordetella pertussis is a human-specific Gram-negative bacterium and the causative agent of
whooping cough, also known as pertussis. This highly contagious disease of the upper respira-
tory tract can be fatal in unvaccinated infants and is the cause of persistent cough among older
children and adults [1]. Whole cell pertussis vaccines (WCVs) were introduced worldwide in
the 1950’s after which the number of notifications decreased dramatically [2]. WCVs were rel-
atively reactogenic and therefore replaced by acellular pertussis vaccines (ACVs) in the 1990’s
in most Western countries [3–5]. In the Netherlands, WCVs were introduced as part of the
national immunization program in 1957 and replaced by ACVs in 2005 [6]. Despite high vac-
cination coverage, cases of pertussis have increased in the past three decades [7]. Possible
explanations for this resurgence include improved diagnosis, increased awareness, waning of
vaccine-induced immunity and genetic changes of B. pertussis (reviewed in [8]). Observed bac-
terial changes include the emergence of strains that carry novel alleles for prn, fim2, fim3, ptxA
and ptxP as well as the non-expression of the vaccine antigen pertactin (Prn) [9–11]. A mix of
ptxP1 (P1) and ptxP2 (P2) strains were prevalent before the introduction of the WCVs and
were used to produce the pertussis vaccines. After the introduction of the WCVs mainly P1
strains circulated [12, 13]. The ptxP3 (P3) strains emerged in the 1980’s and represent more
than 90% of the current B. pertussis populations in many countries worldwide [9, 14]. These
P3 strains have been associated with the resurgence and severity of pertussis [11, 15, 16].
Dendritic cells (DCs) are innate immune cells that sense pathogens by means of pattern rec-
ognition receptors (PRRs) including the Toll-like receptors (TLRs) and the NOD-like recep-
tors [17–19]. Each receptor recognizes a unique pathogenic molecular structure resulting in a
cascade of events leading to NF-κB activation and subsequent cytokine production [20]. Acti-
vation of different PRRs by pathogens is essential for triggering innate immunity and for the
induction and steering of the subsequent adaptive immune response [21, 22].
Although B. pertussis strain adaptation has been extensively studied [23], little is known
about the effect that these bacterial changes may have on innate immune responses to this
pathogen. Here, we characterize PRR and moDC activation induced by genetically diverse B.
pertussis clinical isolates circulating before and after the introduction of the pertussis vaccines.
We observed that all B. pertussis clinical isolates induce TLR2, TLR4 and NOD2 but not
NOD1 signaling in HEK-Blue cells. In addition, we observed an increased activation of TLR2
and NOD2 by strains circulating after, compared to before, the introduction of the pertussis
vaccines. Furthermore, when using moDCs, we observed that recently circulating strains, par-
ticularly the ones that emerged after the introduction of ACVs, induced stronger DC activa-
tion resulting in a dominant increased production of the anti-inflammatory cytokine IL-10
and increased expression of surface markers including the regulatory molecule PD-L1.
These in vitro studies suggest that emerging B. pertussis strains have evolved to induce a
more regulatory response, which could be an immune evasion strategy used by this pathogen
to increase its survival and transmission in a highly vaccinated population.
Materials and Methods
Ethics approval
This study was conducted using blood donations for primary cell isolation, a research goal not
requiring review by an accredited Medical Research Ethics Committee (MREC), as determined
by the Dutch Central Committee on Research Involving Human Subjects (CCMO) (http://
www.ccmo.nl/en/help-me-on-my-way-static) and warranted by a solicited accredited MREC.
The study was conducted according to the principles expressed in the Declaration of Helsinki
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and written informed consent was obtained from all blood donors before collection and anon-
ymous use of their samples.
Bordetella pertussis clinical isolates
In this study, ninety-two B. pertussis strains isolated from pertussis patients were randomly
selected from the B. pertussis strain collection at the National Institute for Public Health and
the Environment, The Netherlands. As shown in Fig 1, the strains were divided into three
groups according to year of isolation: 1) from 1949 to 1960; a period just before and during the
time WCVs were introduced (Introd-Vac-strains), 2) from 1970 to 2000; a period after the
introduction of WCVs (WCV-strains) and 3) from 2005 to 2014; after the introduction of
ACVs (ACV-strains). Table 1 gives an overview of all the strains used in this study, their year
of isolation and the ptxP, prn, fim2, fim3 and ptxA allele type, which was previously determined
[24]. These strains were incubated with the different HEK-Blue cell lines expressing either
TLR2, TLR4, NOD1 or NOD2. In addition to grouping the strains according to their year of
isolation, the strains were also grouped based on the ptxP allele they carried (P1, P2 and P3).
For the experiments using the moDCs, 29 strains were selected from the 92 strains, as repre-
sentative for each of the periods mentioned above. The selection was made based on the PRR
activation levels that the selected strains induced, compared to the PRR activation levels of all
92 strains. As shown in S1 Table, the average SEAP-OD value from the selected strains did not
deviate more than 15% from the average OD value of all tested strains per group and PRR.
From these 29 strains, six Introd-Vac-strains and six ACV-strains were used to determine
their effect on DC maturation as indicated by expression of activations markers on the moDC
cell surface. Six additional Prn-deficient strains were included in the moDC experiments. The
B. pertussis laboratory strain Tohama I (B0213; streptomycin and naladixic acid resistant) was
also included in this study to normalize for possible plate differences. All B. pertussis isolates
were grown at 35˚C on Bordet Gengou (BG) plates containing glycerol and 15% defibrinated
sheep blood (BD Biosciences). After three days of culture, the bacteria were collected in phos-
phate-buffered saline (PBS, Gibco), and the optical density (OD) was measured at 600 nm.
HEK-Blue cell lines and stimulation
To determine which human PRRs are activated by the different B. pertussis clinical isolates,
live bacteria were incubated at a multiplicity of infection (MOI) of 40 with the NF-κB/SEAP
Fig 1. Schematic representation of the time periods in which the strains used in this study were grouped, based on their
year of isolation. The periods included strains isolated before or around the time the WCVs were introduced (Introd-Vac-strains,
1949–1960) and after the introduction of the WCVs (WCV-strains, 1970–2000) or ACVs (ACV-strains, 2005–2014). The three
groups are indicated in green, blue and pink respectively. The WCV was introduced in the Dutch National Immunisation programme
(NIP) in 1957. In 2001, the ACVs were included in the NIP as a four year old (4yo) booster. The WCVs were fully replaced by the
ACVs in 2005 (black arrows).
doi:10.1371/journal.pone.0170027.g001
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Table 1. B. pertussis strains used in this study isolated from Dutch patients between 1949 and 2014.
Strain Year of Isolation ptxP Prn_region1 Prn_region2 fim2 fim3 ptxA Group
B0558 1949 1 1 1 1 2 1950–60
B1195 1949 1 1 1 1 2 1950–60
B0304 1950 1 1 1 1950–60
B0339 1950 1 1 2 1950–60
B0560 1950 2 1 3 1 4 1950–60
B0562 1950 1 2 1 1 1950–60
B0565 1950 1 1 1 2 1950–60
B1197 1950 1 1 1 2 1950–60
B1198 1950 2 7 2 1 4 1950–60
B1200 1950 1 1 1 2 1950–60
B0335 1951 2 1 3 2 1 4 1950–60
B0338 1951 2 3 4 1950–60
B0566 1951 2 1 3 4 1950–60
B0567 1951 2 7 2 1 4 1950–60
B0569 1951 2 1 3 4 1950–60
B0296 1952 1 1 2 1950–60
B0336 1952 1 1 1 1 2 1950–60
B0441 1952 2 7 2 1 4 1950–60
B0571 1952 1 1 1 2 1950–60
B1203 1952 1 1 1 2 1950–60
B0443 1953 1 1 1 2 1950–60
B1363 1955 2 7 2 1 4 1950–60
B1377 1955 2 1 3 1 4 1950–60
B1378 1955 2 1 3 2 1 4 1950–60
B1381 1956 1 1 1 2 1950–60
B1382 1957 2 1 3 1 4 1950–60
B1383 1957 1 1 1 1 2 1950–60
B1384 1957 2 1 3 1 4 1950–60
B1365 1958 1 1 1 1 2 1950–60
B0440 1978 1 1 1 1 1 1970–2000
B0678 1981 1 1 1 1 1970–2000
B2939 1985 1 1 1 1 1 1970–2000
B0760 1987 1 1 1 1 1970–2000
B2965 1987 1 1 1 1 1970–2000
B2969 1987 1 1 1 1 1970–2000
B0834 1988 1 1 1 1 1970–2000
B0861 1989 1 3 1 1970–2000
B0870 1990 1 2 1 1 1970–2000
B0556 1993 1 2 1 1970–2000
B0346 1994 1 3 1 1970–2000
B0354 1994 1 3 1 1970–2000
B0520 1994 1 3 1 1 1970–2000
B0538 1994 1 3 1970–2000
B0541 1994 3 2 1 1970–2000
B0597 1995 1 3 1 1 1970–2000
B0599 1995 1 3 1 1 1970–2000
B0604 1995 1 3 1 1 1970–2000
(Continued )
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Table 1. (Continued)
Strain Year of Isolation ptxP Prn_region1 Prn_region2 fim2 fim3 ptxA Group
B0606 1995 3 2 1 1 1970–2000
B0611 1995 1 3 1 1970–2000
B0661 1996 1 3 1970–2000
B1722 1997 1 1 1 1 1970–2000
B1781 1997 3 2 1 1 1 1970–2000
B1707 1998 3 2 1 1970–2000
B1805 1998 3 2 1 1 1 1970–2000
B1960 1998 3 2 1970–2000
B1826 1999 1 2 1 1 1970–2000
B1895 2000 3 2 1970–2000
B1917 2000 3 2 1 1 2 1 1970–2000
B1927 2000 3 2 1970–2000
B2911 2005 3 2 1 1 1 2005–14
B2914 2005 3 2 1 1 2005–14
B3104 2007 3 2 1 1 1 2005–14
B3107 2007 3 2 1 1 1 1 2005–14
B3115 2007 3 2 S 1 1 1 2005–14
B3130 2007 3 2 1 1 1 1 2005–14
B3134 2007 3 2 1 2 1 2005–14
B3135 2007 3 2 1 1 1 1 2005–14
B3173 2007 3 2 1 1 1 1 2005–14
B3180 2008 3 2 1 1 1 2005–14
B3203 2008 3 2 1 2 1 2005–14
B3212 2008 1 2 1 1 1 2005–14
B3235 2008 13 2 1 1 1 1 2005–14
B3269 2008 3 2 1 1 1 1 2005–14
B3274 2008 3 2 1 1 1 1 2005–14
B3339 2009 3 2 1 1 1 2005–14
B3392 2009 2005–14
B3400 2009 2005–14
B3446 2010 3 2 1 1 1 1 2005–14
B3894 2011 3 2 1 1 1 1 2005–14
B3896 2011 3 1 1 2005–14
B3903 2011 3 2 1 1 2005–14
B3909 2011 3 2 1 1 1 2005–14
B3912 2012 3 2 1 1 1 2005–14
B3915 2012 3 2 1 1 1 1 2005–14
B3916 2012 3 2 1 1 1 1 2005–14
B3924 2012 1 1 1 1 2005–14
B3940 2012 2005–14
B3951 2012 3 2 1 1 1 1 2005–14
B3962 2012 3 2 1 1 1 1 2005–14
B3967 2012 2005–14
B4011 2012 3 2 1 2005–14
B4171 2014 3 2 1 1 1 1 2005–14
B3640 2010 3 2 1 1 1 1 Prn-
B3645 2007 3 2 1 1 1 1 Prn-
(Continued )
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reporter HEK293-Blue (HEK-Blue) cell lines expressing either TLR2 (HEK-Blue-TLR2),
TLR4/MD-2/CD14 (HEK-Blue-TLR4), NOD-1 (HEK-Blue-NOD-1) or NOD-2 (HEK-Blue-
NOD2) (InvivoGen, San Diego, California,USA). To control for endogenous PRR activation,
un-transfected parental HEK-Blue-Null1 cells were also used. All cell lines contained an NF-
kB-inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. PRR signaling
leads to the expression of SEAP, which can be detected in culture supernatants upon addition
of the substrate Quanti-Blue (InvivoGen). The HEK-Blue cells were cultured as previously
described [25]. In short, HEK-Blue cells were stimulated in a volume of 200 μl in 96-wells
plates for 24 hours according to the manufacturer’s instructions. An MOI of 40 was used as
the optimal bacterial concentration based on previous titration experiments using 10-fold bac-
terial dilutions. With a MOI of 40 all HEK-PRR cells responded with SEAP activity values that
fell within the linear range response obtained using the respective positive controls. The exper-
iment was performed on three separate days and to correct for possible plate and day differ-
ences, the laboratory strain Tohama I was taken along on each plate. PRR activation by the
different B. pertussis clinical isolates was expressed as the SEAP activity induced normalized to
the activity induced by the B. pertussis laboratory strain Tohama I.
Purification, culture and stimulation of moDCs
MoDcs were purified from peripheral blood derived from healthy donors and cultured as
described previously [25]. Briefly, after peripheral blood mononuclear cell isolation using a
Lymphoprep (Nycomed, Zurich, Switzerland) gradient, monocytes were collected by using
MACS in combination with anti-CD14 microbeads (Miltenyi Biotech, Bergisch Gladbach,
Germany). Purity of the CD14-positive cells was determined by staining the monocytes with
anti-CD14-PE (BD biosciences,) followed by data acquisition on the FACS Canto II (BD Bio-
sciences) and analysis using FlowJo software (Tree Star). CD14 positive purity was more than
90% for each donor. Monocytes were cultured in 24-well culture plates at 0.4 x 106 cells/well
for 6 days in IMDM culture medium supplemented with 1% FCS, 100 units penicillin, 100
units streptomycin, and 2.92 mg/ml L-glutamine (Gibco; DC culture medium), and in the
presence of 500 U/mL GM-CSF (PreproTech) and 800 U/mL IL-4 (Active biosciences). On day
6, the immature moDCs were either left unstimulated in DC culture medium supplemented
with 500 U/ml GM-CSF or stimulated with live B. pertussis at an MOI of 10 (suboptimal bacterial
concentration based on previous titration experiments) in the presence or absence of 1 μg/ml
polyclonal anti-TLR2 (Invivogen) that was added two hours before adding the B. pertussis
strains. The experiment was performed using moDCs from three separate donors and the labo-
ratory strain Tohama I was taken along to correct for possible donor differences. After 48 hours
Table 1. (Continued)
Strain Year of Isolation ptxP Prn_region1 Prn_region2 fim2 fim3 ptxA Group
B3865 2011 3 2 1 1 1 Prn-
B3876 2011 3 2 1 1 1 1 Prn-
B3977 2012 3 2 1 1 1 1 Prn-
B4172 2014 3 2 1 1 1 1 Prn-
Table 1: Strains were divided into three groups according to year of isolation: strains isolated before and around the time of the WCVs were introduced in the
Netherlands (1950–1960, Introd-Vac-strains), strains isolated during the time the WCVs were used (1970–2000, WCV-strains) and strains isolated during
the time the ACVs were used (2005–2014, ACV-strains). Alleles for the ptxP, prn region one and two, fim2, fim3 and ptxA determined by sequencing are
indicated in the table, when known.
doi:10.1371/journal.pone.0170027.t001
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of incubation, supernatants were collected and filtered using Ultrafree-MC GV centrifugal filers
with a pore size of 0.22 μm (Millipore), and stored at -80˚C for cytokine analysis.
FACS analysis
MoDCs stimulated with six Introd-Vac-strains or six ACV-strains were used to analyze surface
marker expression. These moDC were stained with PE-conjugated anti-CD101 (BD Biosci-
ences), APC-conjugated anti-CD97 (R&D systems), FITC-conjugated anti-CD80 (BD Biosci-
ences), Pacific Blue-conjugated anti-CD86 (BioLegend), PerCP-eFluor710- conjugated anti-
CD274, PE/Cy7-conjugated anti-CD172a/b and with LIVE/DEAD Fixable Aqua Dead Cell
Stain Kit (Invitrogen) for 30 minutes at 4˚C. The moDC were washed twice with FACS buffer
(PBS pH 7.2; 0,5% BSA; 0,5 mM EDTA) and fixed with 1.5% PFA. Data was acquired on FACS
Canto II (BD Biosciences) and analyzed using FlowJo software (Tree Star). More than 90% of
the stimulated cells remained viable after the 48-hour stimulation.
Cytokine analysis
The concentration of the cytokines IL-1β, IL-6, IL-10, MCP-1, MIP-1α, MIP-1β, and TNF-α
was measured in supernatants from moDC that were stimulated for 48 hours, by using a Bio-
rad human 8-plex luminex kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
instructions. Measurements and data analysis were performed with Bio-Plex 200, using Bio-
Plex Manager software (version 5.0; Bio-Rad Laboratories). IL-8 concentration was measured
using an IL-8 ELISA kit (R&D, Minneapolis, MN, USA) which was performed according to
the manufacturer’s instructions. Results are expressed as pg/ml of cytokine production
induced by the different B. pertussis isolates normalized to the cytokine levels induced by the
B. pertussis laboratory strain Tohama I, to correct for possible plate/donor differences.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.04. Statistical significance was
determined by using ANOVA followed by unpaired t-tests. False discovery rate was controlled
at the level of 10% by applying the Benjamini-Hochberg method to the results of all the tests
performed. Results presented as statistically significant have passed the selection based on the
False discovery rate. P values0.05 were considered statistically significant.
Results
Bordetella pertussis strains isolated from patients after the introduction
of pertussis vaccination induce increased activation of human TLR2 and
NOD2
For this study, 92 B. pertussis strains isolated from pertussis patients were divided into three
groups according to the year of isolation: 1) from 1949 to 1960; just before and during the time
WCVs were first introduced, 2) from 1970 to 2000; after the introduction of WCVs and 3)
from 2005 to 2014; after the introduction of ACVs in The Netherlands (Fig 1). Strains from
these three periods were designated Introd-Vac-strains, WCV-strains and ACV-strains,
respectively. In order to determine whether these strains induced TLR2, TLR4, NOD2 and
NOD1 activation, HEK-Blue cells expressing either one of these PRRs were stimulated with
the different B. pertussis clinical isolates. All of the tested strains activated TLR2, TLR4 and
NOD2, but not NOD1 as indicated by the induced SEAP activity (Fig 2A–2D). Fig 2 shows
that activation of TLR2 (Fig 2A) and NOD2 (Fig 2C) was significantly higher when stimulated
with the WCV- as well as the ACV-strains compared to the Introd-Vac-strains. There was no
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significant difference in the activation of these PRRs between the WCV- and ACV-strains. No
significant differences in TLR4 activation by the different group of strains were observed (Fig
2B). To control for non-specific activation all strains were incubated with the parental untrans-
fected HEK-Null cells, which showed no induction of SEAP activity (S1 Fig). Upon grouping
the strains according to the ptxP allele, into the groups P1, P2 and P3, we found significant
increased TLR2 activation by P1 and P3 compared to the older P2 strains (Fig 2E). The P3
strains also showed an increased activation of NOD2 compared to P2 strains (Fig 2G) and a
small but significant increase in TLR4 activation by P3 compared to the P2 strains was
observed (Fig 2F). No difference between TLR2, TLR4 and NOD2 activation by P1 compared
to P3 strains was detected. In order to determine whether mutations in B. pertussis gene
sequences could explain the observed TLR2 activation differences, we compared the sequence
of genes encoding the B. pertussis lipoproteins BP1569 and BP2992, which were recently
shown to be TLR2 agonists [26]. From the strains used in this study, whole genome sequence
data was only available for B1917, B0296, B0558 and B1281. Therefore, a Blast search of 340 B.
pertussis whole genome sequences available in the NCBI database, which contains 60 Dutch
strains, was performed [27]. Sequence data analysis did not reveal any polymorphism for the
above mentioned B. pertussis lipoproteins genes in strains carrying the ptxP1, ptxP2 or ptxP3
alleles.
Increased IL-10 production and regulatory surface marker expression by
moDCs upon stimulation with B. pertussis strains isolated after the
introduction of pertussis vaccines
In addition to using the HEK-Blue reporter cells expressing individual PRRs to screen for
innate immune activation by emerging B. pertussis strains, moDCs isolated from peripheral
blood of healthy donors were used. These cells were stimulated with a selection of 29 B. pertus-
sis strains representing the three different periods, based on the average PRR activation levels
of the selected 29 strains compared to all strains. Results show increased moDC activation
upon stimulation with the ACV- compared to Introd-Vac-strains, with a dominant produc-
tion of IL-10 and to a lesser extent of G-CSF by these cells (Fig 3A and 3B). Moreover, ACV-
strains induced a significant increased production of IL-10 compared to WCV-strains (Fig
3A). A small but significant increased production of TNF-α and IL-8 was also observed when
comparing WCV-strains to Introd-Vac-strains and ACV-strains to WCV-strains respectively
(Fig 3C and 3D). In addition to cytokine production, expression of the surface markers CD80,
CD86, CD101, CD172a/b, CD274 (PD-L1) and CD97 on moDC stimulated with Introd-Vac-
strains or ACV-strains was analyzed using flow cytometry. Fig 4A–4D shows a significant
increase in CD80, CD86, PD-L1 and CD101 surface expression on moDC stimulated with
ACV-strains compared to Introd-Vac-strains (Fig 4A–4D). As shown in Fig 4E, the expression
of PD-L1 was decreased on moDCs stimulated with ACV-strains in the presence compared to
Fig 2. Activation of human TLR2, TLR4, NOD2 and NOD1 by B. pertussis strains isolated from
patients from 1949 to 2014. HEK-Blue cell lines either expressing TLR2, TLR4, NOD2 or NOD1 were
stimulated with 92 different B. pertussis strains (MOI 40) isolated from pertussis patients either around the time
the WCVs were introduced (Introd-Vac-strains) or when the WCVs (WCV-strains) or ACVs (ACV-strains) were
used. PRR activation measured by SEAP activity of (A) HEK-Blue-TLR2 cells, (B) HEK-Blue-TLR4 cells, (C)
HEK-Blue-NOD2 cells or (D) HEK-Blue-NOD1 cells by Introd-Vac-strains (1949–1960), WCV-strains (1970–
2000) and ACV-strains (2005–2014). SEAP activity induced by these same strains grouped according to their
ptxP alleles, ptxP1 (P1), ptxP2 (P2) or ptxP3 (P3), upon stimulation of (E) HEK-Blue-TLR2, (F) HEK-Blue-
TLR4 cells or (G) HEK-Blue-NOD2 cells. SEAP activity of cells in medium only or with the respective ligands,
Pam3CSK4 (100ng/ml), LPS-EK (10ng/ml), MDP (200ng/ml) or iE-DAP (100ng/ml) are included for each
HEK-Blue cell line. * p 0.05, ** p 0.01, **** p 0.0001.
doi:10.1371/journal.pone.0170027.g002
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the absence of the TLR2 blocker. No difference in the levels of the other surface markers or
cytokines was observed in the presence of the blocking TLR2 antibody. The levels of other
Fig 3. Cytokine production by moDCs stimulated with B. pertussis strains isolated from patients from 1949 to 2014. MoDCs were
stimulated with 29 different strains either isolated around the time the WCVs were introduced (Introd-Vac-strains) or when the WCVs (WCV-strains)
or ACVs (ACV-strains) were used at an MOI of 10. MoDC production of (A) IL-10, (B) G-CSF, (C) TNF-α and (D) IL-8 production by Introd-Vac-
strains (1949–1960), WCV-strains (1970–2000) and ACV-strains (2005–2014). Medium stimulation values for IL-8, TNF-α, G-CSF and IL-10 are
depicted in the appropriate graphs * p 0. 05, ** p 0.01, **** p 0.0001.
doi:10.1371/journal.pone.0170027.g003
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Fig 4. Surface marker expression of moDCs stimulated with Introd-Vac and ACV- B. pertussis strains
isolated from pertussis patients. MoDCs were stimulated with 12 different B. pertussis strains (MOI 10)
isolated from patients at around the time the WCVs were introduced (Introd-Vac-strains) or when the ACVs
(ACV-strains) were used, either in the presence or absence of 1 μg/ml anti-TLR2 blocking antibody. MoDC
surface expression of (A) CD80, (B) CD86, (C) PD-L1/CD274 and (D) CD101 by Introd-Vac-strains (1949–
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cytokines namely, IL-6, MCP-1, MIP-1α and MIP-1β, as well as the surface markers CD97 and
CD172 showed no significance difference when moDCs were stimulated with the strains iso-
lated from the different periods (S2 Fig). The levels of IL-1β and IL-12 were either very low or
undetectable upon stimulation with the different B. pertussis strains.
Recently circulating P3 strains induce increased IL-10 production
compared to older P3 strains
Characterization of genetically diverse groups of B. pertussis strains that have emerged over time
have been previously reported [28]. Based on the sequence of the carried ptxP allele several groups
of B. pertussis strains can be distinguished [29]. Older strains generally carry the P2 allele, whereas
90% of the currently circulating strains carry the P3 allele [9]. To determine whether ptxP allele
carriage is associated with the observed moDC cytokine production induced by emerging B. per-
tussis strains, we grouped the strains according to their ptxP allele in the groups P2, P1 and P3.
Results indicate that there were no significant differences in IL-10 (Fig 5A), TNF-α (Fig 5C) or
IL-8 (Fig 5D) production by moDC when comparing the strains carrying different ptxP alleles. A
significant increase in G-CSF production induced by P3 strains compared to P2 strains was
observed (Fig 5B). Notably, when comparing the P3 strains isolated before (n = 5) and after the
introduction of the ACV (n = 7), we observed that the more recently isolated P3 strains induced a
significantly increased production of IL-10 by moDCs (Fig 5E) and an increased trend, although
not significant, in activation of TLR2 and NOD2 (S3 Fig). No difference in the levels of G-CSF,
TNF-α or IL-8 production was detected upon stimulating moDCs with the older vs recently cir-
culating P3 strains (Fig 5F–5H).
Prn-deficient B. pertussis strains induce a comparable moDC cytokine
profile as Prn-expressing strains
In recent years, B. pertussis P3 strains that do not express the vaccine antigen Prn have been
emerging in countries that use the ACVs [30–34]. In some countries, more than 80% of the
strains isolated no longer express this virulence factor [32, 33]. In order to determine whether
this lack of Prn expression has an effect on moDC activation, six Prn deficient clinical isolates
were included for moDC stimulation. No difference in the levels of all tested cytokines, includ-
ing IL-10, G-CSF, TNF-α and IL-8 (Fig 6A–6D) were observed when comparing stimulation
with strains that either express Prn or are deficient for Prn.
Discussion
Despite high vaccination coverage, pertussis has reemerged affecting not only infants but also
older individuals [35, 36]. Knowledge on how this bacterium persists in a vaccinated popula-
tion is fundamental. Here, we aimed at determining the effect of emerging B. pertussis strains
on innate immune responses. To this purpose, we investigated the activation of different
human PRRs as well as moDCs by B. pertussis strains isolated from pertussis patients during
the past 65 years in The Netherlands. HEK-Blue cells transfected with different PRRs were
used as a high throughput screening system to detect activation of individual receptors by the
1960) and ACV-strains (2005–2014) alone. (E) MoDC surface expression of PD-L1/CD274 by Introd-
Vac-strains (1949–1960) and ACV-strains (2005–2014) in the presence or absence of 1 μg/ml anti-TLR2
blocking antibody. Medium stimulation values for CD80, CD86, PD-L1/CD274 and CD101 are depicted in
the corresponding graphs * p 0. 05, ** p 0.01, *** p 0.001, **** p 0.0001.
doi:10.1371/journal.pone.0170027.g004
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B. pertussis strains. Findings indicate an increase in TLR2 activation by B. pertussis post-vacci-
nation compared to pre-vaccination strains. TLR2 forms a heterodimer with either TLR1 or
TLR6 and recognizes lipoproteins [37]. Recently, BP1569 and BP2992 from B. pertussis were
identified as TLR2 activating lipoproteins [26]. A Blast search of 340 B. pertussis whole genome
sequences [27] revealed no polymorphism for these genes in strains carrying the ptxP1, ptxP2
or ptxP3 alleles.These findings suggest that differential gene expression or post-translational
modifications may explain the observed differences or that other TLR2 ligands are involved.
For example, FHA has been proposed as a TLR2 ligand although this remains debatable [38,
39].
Modifications of the lipooligosaccharide (LOS) structure from B. pertussis strains has previ-
ously been reported to alter TLR4 signalling and DC activation [25, 40]. We observed no dif-
ferences in TLR4 activation by strains from the three periods indicating no structural
modifications of the LOS molecule from these B. pertussis strains. Other PRRs investigated in
this study were NOD1 and NOD2. Murine NOD1 was previously shown to interact with tra-
cheal cytotoxin (TCT), a B. pertussis toxin specifically destroying ciliated cells [41]. The authors
reported that this virulence factor did not induce signaling of human NOD1, which is in line
with our findings using live B. pertussis. Interestingly, we found that all the B. pertussis strains
used in this study induced NOD2 signaling and that the post-vaccination strains induced sig-
nificantly higher NOD2 activation compared to the pre-vaccination strains. To our knowledge,
we are the first to show that live B pertussis can activate this PRR. NOD2 recognizes peptido-
glycans containing the muramyl dipeptide moiety (N-acetylmuramyl-L-alanyl-D-isogluta-
mine) that are present in Gram-positive and negative bacteria [42]. Further studies are
required to identify B. pertussis derived peptidoglycan moieties responsible for NOD2 activa-
tion. In addition, genomic, transcriptomic and/or proteomic studies may aid in determining
whether the observed increased NOD2 activation is due to changes of gene expression or in
the structure of the B. pertussis ligand(s) for NOD2.
Using the physiologically relevant moDCs, we observed differences in cytokine production
as well as surface marker expression after stimulation with the different groups of B. pertussis
strains. Findings indicate that post-vaccination strains induce increased DC activation. Inter-
estingly, the most striking difference was an increase in the levels of the anti-inflammatory
cytokine IL-10 produced by moDCs when stimulated with ACV-strains compared to Introd-
Vac-strains. Besides its direct anti-inflammatory effect, this cytokine has been shown to be
involved in the induction of regulatory T cells (Tregs) that play a role in controlling inflamma-
tion [43]. An increased anti-inflammatory response can benefit pathogen survival. For example,
increased IL-10 production has been shown to be beneficial for Bordetella parapertussis (a Bor-
detella species also infecting humans) infection in mice by limiting a protective IFN-γresponse
[44]. In addition to IL-10, we also observed an increase in G-CSF production by moDC upon
stimulation with ACV-strains compared to Introd-Vac strains. G-CSF has also been implicated
in the development of tolerogenic DCs and the induction of Tregs [45, 46]. Furthermore, upon
comparison of several surface markers on moDC either stimulated with Introd-Vac- or ACV-
Fig 5. Cytokine production by moDCs stimulated with B. pertussis strains isolated from patients from
1949 to 2014 grouped according to ptxP allele. moDCs were stimulated with 29 different strains either
expressing the ptxP2 (P2), ptxP1 (P1) or ptxP3 (P3) allele, isolated around the time the WCVs were introduced
(Introd-Vac-strains) or when the WCVs (WCV-strains) or ACVs (ACV-strains) were used at an MOI of 10.
MoDC production of (A) IL-10, (B) G-CSF, (C) TNF-α and (D) IL-8 production by P2, P1 and P3 strains. The
production of (E) IL-10, (F) G-CSF, (G) TNF-α and (H) IL-8 upon stimulation of MoDC by P3 strains isolated
from 1995–2000 or P3 strains isolated from 2005–2014 was also investigated. Medium stimulation values for
IL-8, TNF-α, G-CSF and IL-10 are depicted in the appropriate graphs * p0. 05, ns = non-significant.
doi:10.1371/journal.pone.0170027.g005
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strains, we detected an increased surface expression of the regulatory markers PD-L1 and
CD101. The PD-L1 molecule on DCs can interact with PD-1 on T cells. PD1 is an inhibitory
receptor, which is expressed on activated T cells and activation of this receptor results in
Fig 6. Cytokine production by moDCs stimulated with recently circulating Prn deficient or Prn expressing B. pertussis strains isolated from
patients. MoDC production of (A) IL-10, (B) G-CSF, (C) TNF-α and (D) IL-8 production upon stimulation with P3 strains either expressing (Prn+) or not
expressing Prn (Prn-). Medium stimulation values for IL-8, TNF-α, G-CSF and IL-10 are depicted in the corresponding graphs. ns = non-significant.
doi:10.1371/journal.pone.0170027.g006
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regulation of T cell activation [47]. CD101 is known to inhibit T cell proliferation via the pro-
duction of IL-10 by DCs [48]. The increased expression of these surface markers further
strengthens our hypothesis that B. pertussis is evolving towards a phenotype that induces a
stronger regulatory response.
In addition to the increased expression of regulatory markers, we observed increased expres-
sion of the activation markers CD80 and CD86 which is in accordance with the observed small
but significant, increased production of IL-8 and TNF-α upon stimulation of moDC with the
ACV-strains. The PRRs TLR2 and NOD2 have been reported to cross-talk and play a role in
immune regulation as well as to influence the expression of one another [49]. TNF-α produc-
tion has been shown to be enhanced upon simultaneous activation of NOD2 and TLR2, which
could in part explain the increased TNF-α production by moDCs observed for ACV-strains
compared to Introd-Vac strains [50]. Furthermore, cross-talk between TLR2 and NOD2 can
induce anti-inflammatory signals in which IL-10 plays an important role [51, 52]. In order to
address the role of TLR2 in the observed effect on moDCs by ACV-strains, we made use of a
TLR2 blocking antibody. When blocking TLR2, although the levels of the cytokines were not
altered, we observed that the expression of PD-L1 on these cells was reduced. This observation
hints towards a role for TLR2 activation by B. pertussis in the expression of PD-L1 on these anti-
gen presenting cells. This has previously been described for Streptococcus pneumoniae, that was
shown to regulate PD-L1 expression on DCs in a TLR2 dependent manner [53]. Co-culture
experiments using moDCs and T cells are required to determine whether these emerging strains
indeed steer T cells towards a regulatory phenotype.
Over time P3 strains have emerged and make up over 90% of the currently circulating B
pertussis population in Western countries [12]. To determine whether the observed DC pheno-
type induced by ACV-strains was associated with the emergence of the P3 allele, the strains
used in this study were additionally divided into three groups namely, P1, P2 and P3. Although
we observed an increased activation of TLR2 and NOD2 by P3 strains compared to P2 strains,
no difference in cytokine production by moDCs, including IL-10, was detected. However, P3
strains isolated after the introduction of ACVs induced higher levels of IL-10 compared to P3
strains isolated before this time. This suggests that the increased anti-inflammatory cytokine
induction by emerging B. pertussis strains cannot be attributed to carriage of the ptxP3 allele.
The presence of other polymorphic genetic loci, not necessarily linked to ptxP3, could be
involved in the induction of IL-10. Whole genome sequencing of these strains may resolve this
issue in future studies. Besides changes in ptxP alleles, changes in alleles encoding for Prn and
fimbriae have also been reported [12]. Unfortunately, due to the low numbers of strains carry-
ing similar sets of alleles, we were not able to determine whether combinations of alleles, or
specific sequence types, were associated with the observed increased in anti-inflammatory
cytokine production.
A most recent and striking adaptation of B. pertussis is the lack of expression of the vaccine
antigen Prn. In countries were ACVs have been used for more than three decades, up to 85%
of the circulating B. pertussis strains have been reported to no longer express Prn [30–34]. In
2015, the percentage of circulating Prn deficient strains was 14% in The Netherlands (Personal
communication). This mutation has been suggested to be caused by (ACV) vaccine pressure,
as Prn deficient strains show increased survival in mice vaccinated with ACVs compared to
Prn-expressing strains [54, 55]. Furthermore, Prn-deficient strains are predominantly isolated
from pertussis patients vaccinated with ACVs compared to unvaccinated patients [56, 57].
When we compared the cytokine profile of moDCs upon stimulation with strains either
expressing or deficient in Prn, we found no differences. This finding indicates that the pres-
ence or absence of Prn in this pathogen has no effect on cytokine production by moDC.
Emerging B. pertussis Strains Induce an Altered DC Phenotype
PLOS ONE | DOI:10.1371/journal.pone.0170027 January 11, 2017 16 / 21
The reemergence of pertussis has been attributed to several factors including bacterial strain
adaptation [8]. Nonetheless, no studies have explored the effect of B pertussis strains emerging
after the introduction of the pertussis vaccines on the host innate immune responses. This
work pioneers in revealing a difference in innate immune activation by recently emerging
strains compared to older strains on which our current vaccines are based. It also illustrates
that the reporter HEK-blue cell lines expressing different PRRs can be used as screening plat-
form to identify innate immune recognition and activation by B. pertussis strains.
Before the introduction of pertussis vaccination, B. pertussis mainly infected naïve individu-
als. Since nowadays most individuals have received a pertussis vaccination and thus have pre-
existing vaccine-induced immunity to B. pertussis, this pathogen is in general no longer infect-
ing a naïve host. Based on the findings here described, we propose that B. pertussis is evolving
towards a phenotype that steer the host immune response towards a regulatory type, which
could benefit bacterial survival and transmission in vaccinated hosts. This and further knowl-
edge on innate immune activation by emerging strains is important to consider in the light of
designing improved pertussis vaccines.
Supporting Information
S1 Fig. Control HEK-Blue Null (untransfected HEK-Blue cells) activation by B. pertussis
strains and TLR ligands. HEK-Blue Null cells were stimulated with medium or live B. pertus-
sis strains at a MOI of 40. The B. pertussis strains used were isolated either around the time the
WCVs were introduced (Introd-vac-strains) or when the WCVs (WCV-strains) or ACVs
(ACV-strains) were used. Furthermore, HEK-Blue Null cells were stimulated with one of the
TLR ligands namely Pam3CSK4 (100ng/ml, TLR2), LPS-EK (100ng/ml, TLR4), iE-DAP
(200ng/ml, NOD1) or MDP (200ng/ml, NOD2). HEK-Blue Null TLR activation was deter-
mined by measuring SEAP activity at an OD 650nm.
(TIF)
S2 Fig. moDC activation by B. pertussis strains isolated from patients from 1949 to 2014.
moDCs were stimulated with 29 different strains either isolated around the time the WCVs
were introduced (Introd-Vac-strains) or when the WCVs (WCV-strains) or ACVs (ACV-
strains) were used. MoDC activation measured by (A) IL-6, (B) MCP-1, (C) MIP-1-α and (D)
MIP-1-β production by Introd-Vac-strains (1950–1960), WCV-strains (1970–2000) and
ACV-strains (2005–2014). No IL-1β or IL-12 production could be detected. Medium stimula-
tion values for IL-6, MCP-1, MIP-1-α, MIP-1-β and IL-1β are depicted in the corresponding
graphs. To determine surface marker expression, moDCs were stimulated with 12 different B.
pertussis strains isolated either around the time the WCVs were introduced (Introd-Vac-
strains) or when the ACVs (ACV-strains) were used at a MOI of 10. MoDC surface expression
of (E) CD97 and (F) CD172 by Introd-Vac-strains (1949–1960) and ACV-strains (2005–2014).
Medium stimulation values for CD97 and CD172 are depicted in the corresponding graphs.
(TIF)
S3 Fig. Activation of human TLR2, NOD2 and TLR4 by P3 WCV- and ACV- B. pertussis
strains. HEK-Blue cell lines either expressing TLR2, TLR4, NOD2 or NOD1 were stimulated
with P3 B. pertussis strains (MOI 40) isolated either when the WCVs (WCV-strains) or ACVs
(ACV-strains) were used. TLR activation measured by SEAP activity of (A) HEK-Blue-TLR2
cells, (B) HEK-Blue-NOD2 cells or (C) HEK-Blue-TLR4 cells by P3-WCV-strains (1970–2000)
and P3-ACV-strains (2005–2014). SEAP activity of cells in medium only or with the respective
ligands, Pam3CSK4 (100ng/ml), LPS-EK (10ng/ml), MDP (200ng/ml) or iE-DAP (100ng/ml)
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are included for each HEK-Blue cell line.
(TIF)
S1 Table. B. pertussisstrain selection for moDC stimulation. Twenty-nine strains were
selected as representative for each group based on their secreted embryonic alkaline phospha-
tase (SEAP) levels of PRR (TLR2, TLR4 and NOD2) activation represented as OD values. The
average OD of the selected strains (Avg OD) did not deviate more than 15% from the average
SEAP OD of all the strains in the respective group (Avg ODallstrains) (Introd-Vac, WCV or
ACV-strains). Strains indicated in bold were used for the analysis of surface marker expres-
sion.
(PDF)
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